Skip to main content


Fig. 2 | Chinese Journal of Cancer

Fig. 2

From: Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

Fig. 2

Comparison of overall survival between the HT group and the MCT group. a Estimation of overall survival, censored on the date of last assessment. b Forest plot (OS analysis); HR < 1 favors HT. DFS disease-free survival, FCCT first-line capecitabine-based combination chemotherapy, KPS Karnofsky performance status, CR complete response, PR partial response, SD stable disease, HT hormonal therapy, HR hazard ratio, CI confidence interval, MCT maintenance capecitabine monotherapy

Back to article page